An experimental model for Huntington's chorea?
- PMID: 24412685
- DOI: 10.1016/j.bbr.2013.12.036
An experimental model for Huntington's chorea?
Abstract
Clinically, Huntington's disease (HD) is well known for the predominant motor symptom chorea, which is a hyperkinetic motor disorder. The only experimental model currently described in the literature, as far as we are aware of, exhibiting hyperkinetic movements is the transgenic rat model of HD. We assessed and characterized these hyperkinetic movements in detail and investigated the effect of tetrabenazine (TBZ) treatment. TBZ is an effective drug in the treatment of chorea in HD patients. Our results showed that the hyperkinetic movements fulfilled the clinical-behavioral criteria of a choreiform movement. Administration of TBZ reduced the number of these hyperkinetic movements substantially. These findings suggest that the hyperkinetic movements observed in this animal model can be considered as a choreiform movement disorder. This makes these animals unique and provides opportunities for chorea-research.
Keywords: Chorea; Dopamine; Huntington's disease; Tetrabenazine; Transgenic rat model.
Copyright © 2014 Elsevier B.V. All rights reserved.
Similar articles
-
Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.Clin Ther. 2012 Jul;34(7):1487-504. doi: 10.1016/j.clinthera.2012.06.010. Epub 2012 Jun 28. Clin Ther. 2012. PMID: 22749259 Review.
-
Tetrabenazine in the treatment of hyperkinetic movement disorders.Expert Rev Neurother. 2006 Jan;6(1):7-17. doi: 10.1586/14737175.6.1.7. Expert Rev Neurother. 2006. PMID: 16466307 Review.
-
Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders.Expert Rev Neurother. 2011 Nov;11(11):1509-23. doi: 10.1586/ern.11.149. Expert Rev Neurother. 2011. PMID: 22014129 Review.
-
Tetrabenazine treatment for Huntington's disease-associated chorea.Clin Neuropharmacol. 2002 Nov-Dec;25(6):300-2. doi: 10.1097/00002826-200211000-00003. Clin Neuropharmacol. 2002. PMID: 12469001 Clinical Trial.
-
Treatment of chorea associated with Huntington's disease: focus on tetrabenazine.Consult Pharm. 2009 Jul;24(7):524-37. doi: 10.4140/tcp.n.2009.524. Consult Pharm. 2009. PMID: 19689181 Review.
Cited by
-
Mitochondrial modulators improve lipid composition and attenuate memory deficits in experimental model of Huntington's disease.Mol Cell Biochem. 2015 Dec;410(1-2):281-92. doi: 10.1007/s11010-015-2561-5. Epub 2015 Sep 15. Mol Cell Biochem. 2015. PMID: 26374445
-
Early Alterations in Operant Performance and Prominent Huntingtin Aggregation in a Congenic F344 Rat Line of the Classical CAGn51trunc Model of Huntington Disease.Front Neurosci. 2018 Jan 25;12:11. doi: 10.3389/fnins.2018.00011. eCollection 2018. Front Neurosci. 2018. PMID: 29422836 Free PMC article.
-
Coexistence of Gait Disturbances and Chorea in Experimental Huntington's Disease.Behav Neurol. 2015;2015:970204. doi: 10.1155/2015/970204. Epub 2015 May 6. Behav Neurol. 2015. PMID: 26063966 Free PMC article.
-
Synaptic Dysfunction in Huntington's Disease: Lessons from Genetic Animal Models.Neuroscientist. 2022 Feb;28(1):20-40. doi: 10.1177/1073858420972662. Epub 2020 Nov 16. Neuroscientist. 2022. PMID: 33198566 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical